2021 ASCO Review on Nivo + Ipi vs. Chemo as 1L Treatment for Advance…

Luis Paz-Ares

1L Nivo + Ipi + 2 Cycles of Chemo vs. Chemo Alone (4 Cycles) in mNSC…

Filippo de Marinis

2021 ASCO Update on 1L Nivo + Ipi + 2 Cycles of Chemo vs. Chemo Alon…

Tom John

1L Nivo+Ipi+Chemo for Patients With Advanced NSCLC and Brain Mets: R…

ecancer

D. Carbone

ESMO 2021 Updates on 1L Nivo+Ipi for Unresectable Malignant Pleural …

ecancer

S. Peters

ASCO 2021 Update on IO in NSCLC: Considering Data From the Key Trials

ecancer

L. Raez

2021 ASCO Updates on Lung Cancer: (Neo)adjuvant Therapy, Metastatic …

UAB Medicine Hematology and Oncology Highlights 2021

A. Hegde

Standard 1L Treatment of Advanced NSCLC in 2021: IO Combination & Mo…

Mariam Alexander

Epidemiological Shifts in Lung Cancers: Trends in Treatment and Diag…

Keck School of Medicine of USC Advancing Knowledge in Multidisciplinary Lung Cancer Care

E. David

Serum Proteomic Signature & Advanced NSCLC: Can It Be Used as an Out…

Northwestern Medicine Oncology and Hematology

Y. Chae

Neoadjuvant Treatment of NSCLC With Immune CPIs: Biological Understa…

CECOG Academy

C. Zielinski

USC Updates on RT for mNSCLC: Consolidative Local Therapy

Keck School of Medicine of USC Advancing Knowledge in Multidisciplinary Lung Cancer Care

M. Daly

Metastatic NSCLC: Approaches and Updates

2022 West Oncology Conference

J. Porter

ASCO 2022 on Clinical and Genomic Characteristics of Pts With Durabl…

ASCO 2022 Conference Coverage

J. Sands

Lecture Summary - ASCO 2022 on Clinical and Genomic Characteristics …

ASCO 2022 Conference Coverage

J. Sands

Lecture Summary - ASCO 2022 on ctDNA Shed as a Tool to Select Immune…

ASCO 2022 Conference Coverage

B. Besse

ASCO 2022 on Immunotherapy Updates in Advanced NSCLC

Nebraska Oncology Society

J. Brahmer

ASCO 2022 3-Year Update From CheckMate 9LA: 1L Nivo + Ipi + 2 Cycles…

ASCO 2022 Conference Coverage

L. Paz-Ares

Lecture Summary - ASCO 2022 3-Year Update From CheckMate 9LA: 1L Niv…

ASCO 2022 Conference Coverage

L. Paz-Ares

Penn Medicine mNSCLC Updates

Penn Medicine Abramson Cancer Center

M. Marmarelis

ASCO 2022 Five-Year Survival Outcomes From CheckMate 227: Nivo + Ipi…

ASCO 2022 Conference Coverage

L. Paz-Ares

ASCO 2022 Early Stage NSCLC Updates

Lung Cancer Europe (LuCE)

J. Naidoo

1L Therapy for Advanced/Metastatic PD-L1 Negative (TPS <1%) NSCLC

Aaron Franke

WCLC 2022 on Modifiable Biomarkers of Response to Immune Checkpoint …

WCLC 2022 Conference Coverage

D. Spakowicz

Lecture Summary - WCLC 2022 on Modifiable Biomarkers of Response to …

WCLC 2022 Conference Coverage

D. Spakowicz

Neoadjuvant vs. Adjuvant Immunotherapy From the Surgeon's Perspective

ILCC 2022 Conference Coverage

T. Mitsudomi

ESMO 2022 on the CheckMate 9LA Study Results: Clinical Outcomes in P…

ESMO 2022 Conference Coverage

T. John

Neoadjuvant Chemotherapy and Immunotherapy for NSCLC

Giuseppe Banna

Neoadjuvant Nivo + Platinum-Doublet Chemo vs. Chemo for Resectable (…

Nicolas Girard